The DOI matches its Crossref record; 156 of the 156 references it cites were found in a registry or an index.
The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens
Open accessAbstract
The ongoing pandemic of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), poses a grave threat to global public health and imposes a severe burden on the entire human society. Like other coronaviruses, the SARS-CoV-2 genome encodes spike (S) glycoproteins, which protrude from the surface of mature virions. The S glycoprotein plays essential roles in virus attachment, fusion and entry into the host cell. Surface location of the S glycoprotein renders it a direct target for host immune responses, making it the main target of neutralizing antibodies. In the light of its crucial roles in viral infection and adaptive immunity, the S protein is the focus of most vaccine strategies as well as therapeutic interventions. In this review, we highlight and describe the recent progress that has been made in the biosynthesis, structure, function, and antigenicity of the SARS-CoV-2 S glycoprotein, aiming to provide valuable insights into the design and development of the S protein-based vaccines as well as therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
A new coronavirus associated with human respiratory disease in China
Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2008-3 · Cited by 11,688 · cited 2×
“Since SARS-CoV-2 was identified as the causative agent of COVID-19, and its first genome sequence was released immediately and freely by a Chinese research group (40), SARS-CoV-2 vaccine candidates based on various vaccine platforms, such as inactivated or live attenuated vaccines, DNA and mRNA vaccines, viral vector-…”
BackgroundAn interactive web-based dashboard to track COVID-19 in real time
Dong, E., Du, H., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30120-1 · Cited by 10,048
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897 · cited 6×
“When the S ectodomain trimer adopts a partially open conformation, the RBD in the “up” position will abolish the contacts with the S2 subunit of an adjacent protomer, destabilizing the partially open conformation (Figure 2C) (11, 34).”
BackgroundInfluentialStructure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Coronaviridae Study Group of the International Committee on Taxonomy of Viruses, Gorbalenya, A. E., Baker, S. C., Baric, R. S., de Groot, R. J., Drosten, C., Gulyaeva, A. A., Haagmans, B. L., Lauber, C., Leontovich, A. M., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0695-z · Cited by 8,403
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983
Origin and evolution of pathogenic coronaviruses
Cui, J., Li, F., & Shi, Z.-L. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0118-9 · Cited by 5,515
The proximal origin of SARS-CoV-2
Andersen, K. G., Rambaut, A., Lipkin, W. I., Holmes, E. C., & Garry, R. F. (2020) · Nature Medicine · doi:10.1038/s41591-020-0820-9 · Cited by 5,081
Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2
Yan, R., Zhang, Y., Li, Y., Xia, L., Guo, Y., & Zhou, Q. (2020) · Science · doi:10.1126/science.abb2762 · Cited by 5,040
Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E. E., Bhattacharya, T., Foley, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.043 · Cited by 4,281
Structural basis of receptor recognition by SARS-CoV-2
Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Aihara, H., Geng, Q., Auerbach, A., & Li, F. (2020) · Nature · doi:10.1038/s41586-020-2179-y · Cited by 3,661
Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595
Cell entry mechanisms of SARS-CoV-2
Shang, J., Wan, Y., Luo, C., Ye, G., Geng, Q., Auerbach, A., & Li, F. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2003138117 · Cited by 3,142
Letko, M., Marzi, A., & Munster, V. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0688-y · Cited by 3,109
Ou, X., Liu, Y., Lei, X., Li, P., Mi, D., Ren, L., Guo, L., Guo, R., Chen, T., Hu, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15562-9 · Cited by 3,097
Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2
Wang, Q., Zhang, Y., Wu, L., Niu, S., Song, C., Zhang, Z., Lu, G., Qiao, C., Hu, Y., Yuen, K.-Y., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.045 · Cited by 2,892 · cited 1×
“Structurally, RBD consists of two subdomains: a core and an external subdomain (51, 52).”
BackgroundIntracellular Functions of N-Linked Glycans
Helenius, A., & Aebi, A. M. (2001) · Science · doi:10.1126/science.291.5512.2364 · Cited by 2,405
Monteil, V., Kwon, H., Prado, P., Hagelkrüys, A., Wimmer, R. A., Stahl, M., Leopoldi, A., Garreta, E., Hurtado del Pozo, C., Prosper, F., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.004 · Cited by 2,122 · cited 1×
“Recombinant soluble ACE2 (54) and ACE2-Fc (55, 56) have been shown to have potential applications in the prevention and treatment of SARS-CoV-2 infection in vitro.”
MethodSelf-citationThe COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885
Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals
Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853
Hoffmann, M., Kleine-Weber, H., & Pöhlmann, S. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.04.022 · Cited by 1,852 · cited 4×
“In the trans-Golgi network, the SARS-CoV-2 S glycoprotein is proteolytically cleaved by cellular furin or furin-like proteases at the S1/S2 cleavage site, comprising multiple arginine residues that are not found in the closely related SARS-CoV (24, 25).”
BackgroundInfluentialStructural and functional analysis of a potent sarbecovirus neutralizing antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · doi:10.1101/2020.04.07.023903 · Cited by 1,752
Coutard, B., Valle, C., de Lamballerie, X., Canard, B., Seidah, N. G., & Decroly, E. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104742 · Cited by 1,679
The spike protein of SARS-CoV — a target for vaccine and therapeutic development
Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2090 · Cited by 1,661
Tai, W., He, L., Zhang, X., Pu, J., Voronin, D., Jiang, S., Zhou, Y., & Du, L. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0400-4 · Cited by 1,654 · cited 2×
“This minimal form of RBDs of both viruses could serve as a vaccine candidate (100).”
BackgroundSARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Developing Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Site-specific glycan analysis of the SARS-CoV-2 spike
Watanabe, Y., Allen, J. D., Wrapp, D., McLellan, J. S., & Crispin, M. (2020) · Science · doi:10.1126/science.abb9983 · Cited by 1,548
Bosch, B. J., van der Zee, R., de Haan, C. A. M., & Rottier, P. J. M. (2003) · Journal of Virology · doi:10.1128/jvi.77.16.8801-8811.2003 · Cited by 1,489
A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV
Yuan, M., Wu, N. C., Zhu, X., Lee, C.-C. D., So, R. T. Y., Lv, H., Mok, C. K. P., & Wilson, I. A. (2020) · Science · doi:10.1126/science.abb7269 · Cited by 1,463
The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity
Li, Q., Wu, J., Nie, J., Zhang, L., Hao, H., Liu, S., Zhao, C., Zhang, Q., Liu, H., Nie, L., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.012 · Cited by 1,420
SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity
Zhang, L., Jackson, C. B., Mou, H., Ojha, A., Peng, H., Quinlan, B. D., Rangarajan, E. S., Pan, A., Vanderheiden, A., Suthar, M. S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19808-4 · Cited by 1,387
A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
Chi, X., Yan, R., Zhang, J., Zhang, G., Zhang, Y., Hao, M., Zhang, Z., Fan, P., Dong, Y., Yang, Y., et al. (2020) · Science · doi:10.1126/science.abc6952 · Cited by 1,385
Mechanisms of Coronavirus Cell Entry Mediated by the Viral Spike Protein
Belouzard, S., Millet, J. K., Licitra, B. N., & Whittaker, G. R. (2012) · Viruses · doi:10.3390/v4061011 · Cited by 1,368
Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike
Liu, L., Wang, P., Nair, M. S., Yu, J., Rapp, M., Wang, Q., Luo, Y., Chan, J. F.-W., Sahi, V., Figueroa, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2571-7 · Cited by 1,349
Xia, S., Liu, M., Wang, C., Xu, W., Lan, Q., Feng, S., Qi, F., Bao, L., Du, L., Liu, S., et al. (2020) · Cell Research · doi:10.1038/s41422-020-0305-x · Cited by 1,343
Structure-based design of prefusion-stabilized SARS-CoV-2 spikes
Hsieh, C.-L., Goldsmith, J. A., Schaub, J. M., DiVenere, A. M., Kuo, H.-C., Javanmardi, K., Le, K. C., Wrapp, D., Lee, A. G., Liu, Y., et al. (2020) · Science · doi:10.1126/science.abd0826 · Cited by 1,303
Baum, A., Fulton, B. O., Wloga, E., Copin, R., Pascal, K. E., Russo, V., Giordano, S., Lanza, K., Negron, N., Ni, M., et al. (2020) · Science · doi:10.1126/science.abd0831 · Cited by 1,253
Distinct conformational states of SARS-CoV-2 spike protein
Cai, Y., Zhang, J., Xiao, T., Peng, H., Sterling, S. M., Walsh, R. M., Rawson, S., Rits-Volloch, S., & Chen, B. (2020) · Science · doi:10.1126/science.abd4251 · Cited by 1,221 · cited 6×
“However, the native trimeric SARS-CoV-2 S protein could conceal each of its immunodominant RBMs by adopting the closed conformation (41, 83).”
BackgroundInfluentialStudies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
Hansen, J., Baum, A., Pascal, K. E., Russo, V., Giordano, S., Wloga, E., Fulton, B. O., Yan, Y., Koon, K., Patel, K., et al. (2020) · Science · doi:10.1126/science.abd0827 · Cited by 1,210
Harrison, S. C. (2008) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1456 · Cited by 1,190
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
Brouwer, P. J. M., Caniels, T. G., van der Straten, K., Snitselaar, J. L., Aldon, Y., Bangaru, S., Torres, J. L., Okba, N. M. A., Claireaux, M., Kerster, G., et al. (2020) · Science · doi:10.1126/science.abc5902 · Cited by 1,140
A human monoclonal antibody blocking SARS-CoV-2 infection
Wang, C., Li, W., Drabek, D., Okba, N. M. A., van Haperen, R., Osterhaus, A. D. M. E., van Kuppeveld, F. J. M., Haagmans, B. L., Grosveld, F., & Bosch, B.-J. (2020) · Nature Communications · doi:10.1038/s41467-020-16256-y · Cited by 1,132
Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus
McLellan, J. S., Chen, M., Joyce, M. G., Sastry, M., Stewart-Jones, G. B. E., Yang, Y., Zhang, B., Chen, L., Srivatsan, S., Zheng, A., et al. (2013) · Science · doi:10.1126/science.1243283 · Cited by 1,126
SARS-CoV-2 Vaccines: Status Report
Amanat, F., & Krammer, F. (2020) · Immunity · doi:10.1016/j.immuni.2020.03.007 · Cited by 1,120
Ahmed, S. F., Quadeer, A. A., & McKay, M. R. (2020) · Viruses · doi:10.3390/v12030254 · Cited by 1,116
Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen
Pallesen, J., Wang, N., Corbett, K. S., Wrapp, D., Kirchdoerfer, R. N., Turner, H. L., Cottrell, C. A., Becker, M. M., Wang, L., Shi, W., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707304114 · Cited by 1,073 · cited 2×
“In addition, the apparent accessibility of the fusion peptide and HR1 region in published structures of the SARS-CoV-2 S ectodomain trimer as well as their high sequence conservation among CoVs suggests that they would be good immunogen candidates for epitope-focused vaccine design aimed at raising broadly CoV neutral…”
BackgroundStructural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant
Yurkovetskiy, L., Wang, X., Pascal, K. E., Tomkins-Tinch, C., Nyalile, T. P., Wang, Y., Baum, A., Diehl, W. E., Dauphin, A., Carbone, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.032 · Cited by 1,025
DNA vaccine protection against SARS-CoV-2 in rhesus macaques
Yu, J., Tostanoski, L. H., Peter, L., Mercado, N. B., McMahan, K., Mahrokhian, S. H., Nkolola, J. P., Liu, J., Li, Z., Chandrashekar, A., et al. (2020) · Science · doi:10.1126/science.abc6284 · Cited by 997
Kwong, P. D., Doyle, M. L., Casper, D. J., Cicala, C., Leavitt, S. A., Majeed, S., Steenbeke, T. D., Venturi, M., Chaiken, I., Fung, M., et al. (2002) · Nature · doi:10.1038/nature01188 · Cited by 889
Premkumar, L., Segovia-Chumbez, B., Jadi, R., Martinez, D. R., Raut, R., Markmann, A. J., Cornaby, C., Bartelt, L., Weiss, S., Park, Y., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abc8413 · Cited by 868 · cited 1×
“The RBD of SARS-CoV is highly immunogenic (96, 97) and is targeted by most of the neutralizing monoclonal antibodies that have been characterized (98).”
BackgroundNeutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses
Jiang, S., Hillyer, C., & Du, L. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.03.007 · Cited by 847
Quasispecies Theory and the Behavior of RNA Viruses
Lauring, A. S., & Andino, R. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001005 · Cited by 846
TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells
Bestle, D., Heindl, M. R., Limburg, H., Van Lam van, T., Pilgram, O., Moulton, H., Stein, D. A., Hardes, K., Eickmann, M., Dolnik, O., et al. (2020) · Life Science Alliance · doi:10.26508/lsa.202000786 · Cited by 815
A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity
Yang, J., Wang, W., Chen, Z., Lu, S., Yang, F., Bi, Z., Bao, L., Mo, F., Li, X., Huang, Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2599-8 · Cited by 780
Self-citationStructural insights into coronavirus entry
(2019) · Advances in Virus Research · doi:10.1016/bs.aivir.2019.08.002 · Cited by 769
Pre-fusion structure of a human coronavirus spike protein
Kirchdoerfer, R. N., Cottrell, C. A., Wang, N., Pallesen, J., Yassine, H. M., Turner, H. L., Corbett, K. S., Graham, B. S., McLellan, J. S., & Ward, A. B. (2016) · Nature · doi:10.1038/nature17200 · Cited by 765
Coronavirus membrane fusion mechanism offers a potential target for antiviral development
Tang, T., Bidon, M., Jaimes, J. A., Whittaker, G. R., & Daniel, S. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104792 · Cited by 761
Yuan, Y., Cao, D., Zhang, Y., Ma, J., Qi, J., Wang, Q., Lu, G., Wu, Y., Yan, J., Shi, Y., et al. (2017) · Nature Communications · doi:10.1038/ncomms15092 · Cited by 760
Structure and immune recognition of trimeric pre-fusion HIV-1 Env
Pancera, M., Zhou, T., Druz, A., Georgiev, I. S., Soto, C., Gorman, J., Huang, J., Acharya, P., Chuang, G.-Y., Ofek, G., et al. (2014) · Nature · doi:10.1038/nature13808 · Cited by 740
Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26
Lu, G., Hu, Y., Wang, Q., Qi, J., Gao, F., Li, Y., Zhang, Y., Zhang, W., Yuan, Y., Bao, J., et al. (2013) · Nature · doi:10.1038/nature12328 · Cited by 739
N-linked protein glycosylation in the ER
Aebi, M. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.04.001 · Cited by 736
Harrison, S. C. (2015) · Virology · doi:10.1016/j.virol.2015.03.043 · Cited by 697
Mechanisms and principles of N-linked protein glycosylation
Schwarz, F., & Aebi, M. (2011) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2011.08.005 · Cited by 695
Wong, S. K., Li, W., Moore, M. J., Choe, H., & Farzan, M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c300520200 · Cited by 694
Liu, Z., Xiao, X., Wei, X., Li, J., Yang, J., Tan, H., Zhu, J., Zhang, Q., Wu, J., & Liu, L. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25726 · Cited by 691
In situ structural analysis of SARS-CoV-2 spike reveals flexibility mediated by three hinges
Turoňová, B., Sikora, M., Schürmann, C., Hagen, W. J. H., Welsch, S., Blanc, F. E. C., von Bülow, S., Gecht, M., Bagola, K., Hörner, C., et al. (2020) · Science · doi:10.1126/science.abd5223 · Cited by 652
Immunogenicity of a DNA vaccine candidate for COVID-19
Smith, T. R. F., Patel, A., Ramos, S., Elwood, D., Zhu, X., Yan, J., Gary, E. N., Walker, S. N., Schultheis, K., Purwar, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16505-0 · Cited by 601
Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion
Walls, A. C., Xiong, X., Park, Y.-J., Tortorici, M. A., Snijder, J., Quispe, J., Cameroni, E., Gopal, R., Dai, M., Lanzavecchia, A., et al. (2019) · Cell · doi:10.1016/j.cell.2018.12.028 · Cited by 582
Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses
Schmidt, F., Weisblum, Y., Muecksch, F., Hoffmann, H.-H., Michailidis, E., Lorenzi, J. C. C., Mendoza, P., Rutkowska, M., Bednarski, E., Gaebler, C., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20201181 · Cited by 572
Protein Folding in the Endoplasmic Reticulum
Braakman, I., & Hebert, D. N. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a013201 · Cited by 571
Proof of principle for epitope-focused vaccine design
Correia, B. E., Bates, J. T., Loomis, R. J., Baneyx, G., Carrico, C., Jardine, J. G., Rupert, P., Correnti, C., Kalyuzhniy, O., Vittal, V., et al. (2014) · Nature · doi:10.1038/nature12966 · Cited by 555
Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer
Walls, A. C., Tortorici, M. A., Bosch, B.-J., Frenz, B., Rottier, P. J. M., DiMaio, F., Rey, F. A., & Veesler, D. (2016) · Nature · doi:10.1038/nature16988 · Cited by 538
The SARS-CoV-2 Vaccine Pipeline: an Overview
Chen, W.-H., Strych, U., Hotez, P. J., & Bottazzi, M. E. (2020) · Current Tropical Medicine Reports · doi:10.1007/s40475-020-00201-6 · Cited by 511
A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike
Xia, S., Yan, L., Xu, W., Agrawal, A. S., Algaissi, A., Tseng, C.-T. K., Wang, Q., Du, L., Tan, W., Wilson, I. A., et al. (2019) · Science Advances · doi:10.1126/sciadv.aav4580 · Cited by 501
A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS
Dai, L., Zheng, T., Xu, K., Han, Y., Xu, L., Huang, E., An, Y., Cheng, Y., Li, S., Liu, M., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.035 · Cited by 495
Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions
Munro, J. B., Gorman, J., Ma, X., Zhou, Z., Arthos, J., Burton, D. R., Koff, W. C., Courter, J. R., Smith, A. B., Kwong, P. D., et al. (2014) · Science · doi:10.1126/science.1254426 · Cited by 492
Jaimes, J. A., André, N. M., Chappie, J. S., Millet, J. K., & Whittaker, G. R. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.04.009 · Cited by 491
A perspective on potential antibody-dependent enhancement of SARS-CoV-2
Arvin, A. M., Fink, K., Schmid, M. A., Cathcart, A., Spreafico, R., Havenar-Daughton, C., Lanzavecchia, A., Corti, D., & Virgin, H. W. (2020) · Nature · doi:10.1038/s41586-020-2538-8 · Cited by 485
Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19
Juno, J. A., Tan, H.-X., Lee, W. S., Reynaldi, A., Kelly, H. G., Wragg, K., Esterbauer, R., Kent, H. E., Batten, C. J., Mordant, F. L., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0995-0 · Cited by 437
Controlling the SARS-CoV-2 spike glycoprotein conformation
Henderson, R., Edwards, R. J., Mansouri, K., Janowska, K., Stalls, V., Gobeil, S. M. C., Kopp, M., Li, D., Parks, R., Hsu, A. L., et al. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-0479-4 · Cited by 435
Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses
Wang, N., Shang, J., Jiang, S., & Du, L. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00298 · Cited by 425
Walls, A. C., Tortorici, M. A., Frenz, B., Snijder, J., Li, W., Rey, F. A., DiMaio, F., Bosch, B.-J., & Veesler, D. (2016) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3293 · Cited by 412
Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections
Lv, H., Wu, N. C., Tsang, O. T.-Y., Yuan, M., Perera, R. A. P. M., Leung, W. S., So, R. T. Y., Chan, J. M. C., Yip, G. K., Chik, T. S. H., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107725 · Cited by 407
Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G
Stewart-Jones, G. B. E., Soto, C., Lemmin, T., Chuang, G.-Y., Druz, A., Kong, R., Thomas, P. V., Wagh, K., Zhou, T., Behrens, A.-J., et al. (2016) · Cell · doi:10.1016/j.cell.2016.04.010 · Cited by 404
T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV
Liu, W. J., Zhao, M., Liu, K., Xu, K., Wong, G., Tan, W., & Gao, G. F. (2017) · Antiviral Research · doi:10.1016/j.antiviral.2016.11.006 · Cited by 395
Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig
Lei, C., Qian, K., Li, T., Zhang, S., Fu, W., Ding, M., & Hu, S. (2020) · Nature Communications · doi:10.1038/s41467-020-16048-4 · Cited by 392
Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody
Lv, Z., Deng, Y.-Q., Ye, Q., Cao, L., Sun, C.-Y., Fan, C., Huang, W., Sun, S., Sun, Y., Zhu, L., et al. (2020) · Science · doi:10.1126/science.abc5881 · Cited by 386
The intracellular sites of early replication and budding of SARS-coronavirus
Stertz, S., Reichelt, M., Spiegel, M., Kuri, T., Martínez-Sobrido, L., García-Sastre, A., Weber, F., & Kochs, G. (2007) · Virology · doi:10.1016/j.virol.2006.11.027 · Cited by 382
Vulnerabilities in coronavirus glycan shields despite extensive glycosylation
Watanabe, Y., Berndsen, Z. T., Raghwani, J., Seabright, G. E., Allen, J. D., Pybus, O. G., McLellan, J. S., Wilson, I. A., Bowden, T. A., Ward, A. B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16567-0 · Cited by 379
Making Sense of Mutation: What D614G Means for the COVID-19 Pandemic Remains Unclear
Grubaugh, N. D., Hanage, W. P., & Rasmussen, A. L. (2020) · Cell · doi:10.1016/j.cell.2020.06.040 · Cited by 353
Liang, Y., Wang, M.-L., Chien, C.-S., Yarmishyn, A. A., Yang, Y.-P., Lai, W.-Y., Luo, Y.-H., Lin, Y.-T., Chen, Y.-J., Chang, P.-C., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01022 · Cited by 339
N-Linked Protein Glycosylation in the Endoplasmic Reticulum
Breitling, J., & Aebi, M. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a013359 · Cited by 332 · cited 1×
“The unprocessed precursor harbors an endoplasmic reticulum (ER) signal sequence located at the N terminus, which targets the S glycoprotein to the RER membrane and is removed by cellular signal peptidases in the lumen of the ER (14, 15).”
BackgroundD614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization
Weissman, D., Alameh, M.-G., de Silva, T., Collini, P., Hornsby, H., Brown, R., LaBranche, C. C., Edwards, R. J., Sutherland, L., Santra, S., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2020.11.012 · Cited by 324
Coast-to-Coast Spread of SARS-CoV-2 during the Early Epidemic in the United States
Fauver, J. R., Petrone, M. E., Hodcroft, E. B., Shioda, K., Ehrlich, H. Y., Watts, A. G., Vogels, C. B. F., Brito, A. F., Alpert, T., Muyombwe, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.021 · Cited by 320
Evaluation of candidate vaccine approaches for MERS-CoV
Wang, L., Shi, W., Joyce, M. G., Modjarrad, K., Zhang, Y., Leung, K., Lees, C. R., Zhou, T., Yassine, H. M., Kanekiyo, M., et al. (2015) · Nature Communications · doi:10.1038/ncomms8712 · Cited by 299
Progress and Prospects on Vaccine Development against SARS-CoV-2
Zhang, J., Zeng, H., Gu, J., Li, H., Zheng, L., & Zou, Q. (2020) · Vaccines · doi:10.3390/vaccines8020153 · Cited by 282
COVID-19: Emergence, Spread, Possible Treatments, and Global Burden
Keni, R., Alexander, A., Nayak, P. G., Mudgal, J., & Nandakumar, K. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.00216 · Cited by 272
Updated Approaches against SARS-CoV-2
Li, H., Zhou, Y., Zhang, M., Wang, H., Zhao, Q., & Liu, J. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00483-20 · Cited by 258
Self-citationPrabakaran, P., Gan, J., Feng, Y., Zhu, Z., Choudhry, V., Xiao, X., Ji, X., & Dimitrov, D. S. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600697200 · Cited by 238
Structure-Based Vaccine Antigen Design
Graham, B. S., Gilman, M. S. A., & McLellan, J. S. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-121217-094234 · Cited by 234
Rey, F. A., & Lok, S.-M. (2018) · Cell · doi:10.1016/j.cell.2018.02.054 · Cited by 231
Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus
Yong, C. Y., Ong, H. K., Yeap, S. K., Ho, K. L., & Tan, W. S. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01781 · Cited by 224
Dieterle, M. E., Haslwanter, D., Bortz, R. H., Wirchnianski, A. S., Lasso, G., Vergnolle, O., Abbasi, S. A., Fels, J. M., Laudermilch, E., Florez, C., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.06.020 · Cited by 216
Jiang, S., He, Y., & Liu, S. (2005) · Emerging Infectious Diseases · doi:10.3201/1107.050219 · Cited by 215
Insights into RNA synthesis, capping, and proofreading mechanisms of SARS-coronavirus
Sevajol, M., Subissi, L., Decroly, E., Canard, B., & Imbert, I. (2014) · Virus Research · doi:10.1016/j.virusres.2014.10.008 · Cited by 214
The SARS-CoV-2 Spike variant D614G favors an open conformational state
Mansbach, R. A., Chakraborty, S., Nguyen, K., Montefiori, D. C., Korber, B., & Gnanakaran, S. (2021) · Science Advances · doi:10.1126/sciadv.abf3671 · Cited by 206
Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses
Jiang, S., Hillyer, C., & Du, L. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.04.008 · Cited by 199
Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits
Ravichandran, S., Coyle, E. M., Klenow, L., Tang, J., Grubbs, G., Liu, S., Wang, T., Golding, H., & Khurana, S. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abc3539 · Cited by 196
McBride, C. E., Li, J., & Machamer, C. E. (2007) · Journal of Virology · doi:10.1128/jvi.02146-06 · Cited by 182
Glycosylation Quality Control by the Golgi Structure
Zhang, X., & Wang, Y. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.02.030 · Cited by 173
Investigation of ACE2 N-terminal fragments binding to SARS-CoV-2 Spike RBDPreprint
Zhang, G., Pomplun, S. J., Loftis, A. R., Tan, X., Loas, A., & Pentelute, B. L. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.19.999318 · Cited by 164
D614G mutation of SARS-CoV-2 spike protein enhances viral infectivityPreprint
Hu, J., He, C., Gao, Q., Zhang, G., Cao, X., Long, Q., Deng, H., Huang, L., Chen, J., Wang, K., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.20.161323 · Cited by 162
Lontok, E., Corse, E., & Machamer, C. E. (2004) · Journal of Virology · doi:10.1128/jvi.78.11.5913-5922.2004 · Cited by 152
Divergent SARS‐CoV‐2‐specific T‐ and B‐cell responses in severe but not mild COVID‐19 patients
Oja, A. E., Saris, A., Ghandour, C. A., Kragten, N. A. M., Hogema, B. M., Nossent, E. J., Heunks, L. M. A., Cuvalay, S., Slot, E., Linty, F., et al. (2020) · European Journal of Immunology · doi:10.1002/eji.202048908 · Cited by 151
Structure and Immune Recognition of the HIV Glycan Shield
Crispin, M., Ward, A. B., & Wilson, I. A. (2018) · Annual Review of Biophysics · doi:10.1146/annurev-biophys-060414-034156 · Cited by 147
Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins
Zhang, Y., Zhao, W., Mao, Y., Chen, Y., Wang, S., Zhong, Y., Su, T., Gong, M., Du, D., Lu, X., et al. (2020) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra120.002295 · Cited by 144
Burton, D. R. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a030262 · Cited by 140
Quinlan, B. D., Mou, H., Zhang, L., Guo, Y., He, W., Ojha, A., Parcells, M. S., Luo, G., Li, W., Zhong, G., et al. (2020) · doi:10.1101/2020.04.10.036418 · Cited by 140 · cited 1×
“org 7 enhancing antibodies or harmful immune or inflammatory responses (106, 112), all of which could be potentially avoided through structure-based immunogen design to improve immunogenicity (113, 114).”
BackgroundJiang, S., Bottazzi, M. E., Du, L., Lustigman, S., Tseng, C.-T. K., Curti, E., Jones, K. M., Zhan, B., & Hotez, P. J. (2012) · Expert Review of Vaccines · doi:10.1586/erv.12.126 · Cited by 137
Dubrovskaya, V., Tran, K., Ozorowski, G., Guenaga, J., Wilson, R., Bale, S., Cottrell, C. A., Turner, H. L., Seabright, G. E., O'Dell, S. J., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.10.008 · Cited by 136
Structure of the Lassa virus glycan shield provides a model for immunological resistance
Watanabe, Y., Raghwani, J., Allen, J. D., Seabright, G. E., Li, S., Moser, F. A., Huiskonen, J. T., Strecker, T., Bowden, T. A., & Crispin, M. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1803990115 · Cited by 114
Protein and Glycan Mimicry in HIV Vaccine Design
Seabright, G. E., Doores, K. J., Burton, D. R., & Crispin, M. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.04.016 · Cited by 114
Chen, W., Tao, X., Agrawal, A. S., Algaissi, A. A., Peng, B., Pollet, J. B. K., Strych, U., Bottazzi, M. E., Hotez, P. J., Lustigman, S., et al. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.09.061 · Cited by 109
Recent strategies targeting HIV glycans in vaccine design
Horiya, S., MacPherson, I. S., & Krauss, I. J. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1685 · Cited by 108
SnapShot: O-Glycosylation Pathways across Kingdoms
Joshi, H. J., Narimatsu, Y., Schjoldager, K. T.-B. G., Tytgat, H. L. P., Aebi, M., Clausen, H., & Halim, A. (2018) · Cell · doi:10.1016/j.cell.2018.01.016 · Cited by 97
Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2
Anderson, D. E., Tan, C. W., Chia, W. N., Young, B. E., Linster, M., Low, J. G. H., Tan, Y., Chen, M. I.-C., Smith, G. J. D., Leo, Y., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1761267 · Cited by 97
SnapShot: N-Glycosylation Processing Pathways across Kingdoms
Chung, C., Majewska, N. I., Wang, Q., Paul, J. T., & Betenbaugh, M. J. (2017) · Cell · doi:10.1016/j.cell.2017.09.014 · Cited by 96
Targeting host-derived glycans on enveloped viruses for antibody-based vaccine design
Crispin, M., & Doores, K. J. (2015) · Current Opinion in Virology · doi:10.1016/j.coviro.2015.02.002 · Cited by 94
Karthik, K., Senthilkumar, T. M. A., Udhayavel, S., & Raj, G. D. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1796425 · Cited by 91
Antibodies and vaccines against Middle East respiratory syndrome coronavirus
Xu, J., Jia, W., Wang, P., Zhang, S., Shi, X., Wang, X., & Zhang, L. (2019) · Emerging Microbes & Infections · doi:10.1080/22221751.2019.1624482 · Cited by 88
Broer, R., Boson, B., Spaan, W. J. M., Cosset, F., & Corver, J. (2006) · Journal of Virology · doi:10.1128/jvi.80.3.1302-1310.2006 · Cited by 81
Structural Vaccinology for Viral Vaccine Design
Anasir, M. I., & Poh, C. L. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00738 · Cited by 78
Saif, L. J. (2020) · European Medical Journal · doi:10.33590/emj/200324 · Cited by 73
D614G Spike Mutation Increases SARS CoV-2 Susceptibility to NeutralizationPreprint
Weissman, D., Alameh, M., de Silva, T. I., Collini, P., Hornsby, H. R., Brown, R. L., LaBranche, C. C., Edwards, R. J., Sutherland, L. L., Santra, S., et al. (2020) · medRxiv · doi:10.1101/2020.07.22.20159905 · Cited by 72
Vaccines against Coronaviruses: The State of the Art
Conte, C., Sogni, F., Affanni, P., Veronesi, L., Argentiero, A., & Esposito, S. (2020) · Vaccines · doi:10.3390/vaccines8020309 · Cited by 66
Sun, Z., Ren, K., Zhang, X., Chen, J., Jiang, Z., Jiang, J., Ji, F., Ouyang, X., & Li, L. (2020) · Engineering · doi:10.1016/j.eng.2020.07.014 · Cited by 62
Ma, C., Su, S., Wang, J., Wei, L., Du, L., & Jiang, S. (2020) · Microbes and Infection · doi:10.1016/j.micinf.2020.05.004 · Cited by 55
Perspectives on the development of neutralizing antibodies against SARS-CoV-2
Ho, M. (2020) · Antibody Therapeutics · doi:10.1093/abt/tbaa009 · Cited by 49
Novel ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV2Preprint
Iwanaga, N., Cooper, L. M., Rong, L., Beddingfield, B. J., Crabtree, J. M., Tripp, R. A., Qin, X., & Kolls, J. K. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.15.152157 · Cited by 49
ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV-2
Iwanaga, N., Cooper, L. M., Rong, L., Maness, N. J., Beddingfield, B. J., Qin, Z., Crabtree, J. M., Tripp, R. A., Yang, H., Blair, R. V., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103670 · Cited by 49
Mandolesi, M., Sheward, D. J., Hanke, L., Ma, J., Pushparaj, P., Vidakovics, L. P., Kim, C., Ádori, M., Lenart, K., Loré, K., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100252 · Cited by 47
Lewis, G. K., Finzi, A., DeVico, A. L., & Pazgier, M. (2015) · Viruses · doi:10.3390/v7092856 · Cited by 43
Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike ProteinsPreprint
Zhang, Y., Zhao, W., Mao, Y., Chen, Y., Wang, S., Zhong, Y., Su, T., Gong, M., Du, D., Lu, X., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.28.013276 · Cited by 37
What Are the Most Powerful Immunogen Design Vaccine Strategies? A Structural Biologist’s Perspective
Kwong, P. D. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a029470 · Cited by 32
Lack of antibody-mediated cross-protection between SARS-CoV-2 and SARS-CoV infections
Yang, R., Lan, J., Huang, B., Ruhan, A., Lu, M., Wang, W., Wang, W., Li, W., Deng, Y. L., Wong, G., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102890 · Cited by 28
Huang, Y., Owino, S. O., Crevar, C. J., Carter, D. M., & Ross, T. M. (2019) · Journal of Virology · doi:10.1128/jvi.01432-19 · Cited by 25
Divergent SARS-CoV-2-specific T and B cell responses in severe but not mild COVID-19Preprint
Oja, A. E., Saris, A., Ghandour, C. A., Kragten, N. A. M., Hogema, B. M., Nossent, E. J., Heunks, L. M. A., Cuvalay, S., Slot, E., Swaneveld, F. H., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.18.159202 · Cited by 22
Immunogenic profile of SARS-CoV-2 spike in individuals recovered from COVID-19Preprint
Juno, J. A., Tan, H., Lee, W. S., Reynaldi, A., Kelly, H. G., Wragg, K. M., Esterbauer, R., Kent, H. E., Batten, C. J., Mordant, F. L., et al. (2020) · medRxiv · doi:10.1101/2020.05.17.20104869 · Cited by 15
Engineering an ACE2-Derived Fragment as a Decoy for Novel SARS-CoV-2 Virus
Renzi, F., Seamann, A., Ganguly, K., Pandey, K., Byrareddy, S. N., Batra, S. K., Kumar, S., & Ghersi, D. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00180 · Cited by 13
Coronaviruses' sugar shields as vaccine candidates.
Wang, D. (2020) · PubMed · Cited by 11
Duan, L., Du, J., & Liu, X. (2015) · Protein Science · doi:10.1002/pro.2750 · Cited by 10
Self-citationACE2 fragment as a decoy for novel SARS-Cov-2 virusPreprint
Renzi, F., & Ghersi, D. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.06.028647 · Cited by 6
Cited by
Severe covid-19 pneumonia: pathogenesis and clinical management
Attaway, A. H., Scheraga, R. G., Bhimraj, A., Biehl, M., & Hatipoğlu, U. (2021) · BMJ · doi:10.1136/bmj.n436 · Cited by 437
Heinz, F. X., & Stiasny, K. (2021) · npj Vaccines · doi:10.1038/s41541-021-00369-6 · Cited by 363
Rahman, S., Montero, M. T. V., Rowe, K., Kirton, R., & Kunik, F. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1902303 · Cited by 289
SARS-CoV-2 spreads through cell-to-cell transmission
Zeng, C., Evans, J. P., King, T., Zheng, Y.-M., Oltz, E. M., Whelan, S. P. J., Saif, L. J., Peeples, M. E., & Liu, S.-L. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2111400119 · Cited by 246
Dynamic expedition of leading mutations in SARS-CoV-2 spike glycoproteins
Hasan, M., He, Z., Jia, M., Leung, A. C. F., Natarajan, K., Xu, W., Yap, S., Zhou, F., Chen, S., Su, H., et al. (2024) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2024.05.037 · Cited by 3
Metadata
- Authors
- Duan, L., Zheng, Q., Zhang, H., Niu, Y., Lou, Y., & Wang, H.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2020-10-07
- Volume
- 11
- Pages
- 576622-576622
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3092192687
- Cited by
- 408
- References
- 156
- FWCI
- 9.78
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.